Atrix Laboratories Inc. has submitted an Investigational New Drug (IND) application to the Food and Drug Administration to produce its anti-prostate cancer drug, Eligard, in an additional dosage form.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results